Please assess the completion status of the following clinical trial:

Trial Title: Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a new prescription for an oral anticoagulant that had a diagnosis of atrial fibrillation or atrial flutter within the 3 years prior to the date of the prescription~* Patients aged 18 years or older (except Alberta, Nova Scotia, and Ontario, where patients will be aged at least 66 years or older)~Exclusion Criteria:~* Patients with less than one year of data availability prior to cohort entry~* Patients with a diagnosis of valvular disease (including rheumatic heart disease) or prior cardiac valve surgery~* Patients with a diagnosis of venous thromboembolic disease in the year prior to cohort entry~* Patients who underwent hemodialysis in the 90 days prior to cohort entry~* Patients with a hip, femur, or knee surgery in the 30 days prior to cohort entry~* Patients with a diagnosis of antiphospholipid syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Direct oral anticoagulants (DOACs) (Type: None): Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
- Warfarin (Type: None): Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.

Based on this trial design, predict the completion outcome and termination type (if applicable).